Trial · NCT04995120

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma

NCT04995120, Phase 2, Unknown, Fudan University

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma. Trials, record NCT04995120. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04995120

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
NCT number: NCT04995120
Status: Unknown
Phases: Phase 2
Enrollment: 42 participants, estimated
Lead sponsor: Fudan University
Conditions: Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
Interventions: chemotherapy TP regimen combined with Toripalimab
First posted: 2021-08-06
Last updated: 2022-01-18

Source ClinicalTrials.gov

Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Laryngeal Preservation rate at 3-month post-radiotherapy	3-month post-radiotherapy	defined as the absence of any residual disease that would justify salvage total laryngectomy
Secondary	Overall response rate of induction therapy	2 weeks after the 3th cycle of induction therapy	Overall response rate of induction therapy evaluated by head and neck MR/CT, laryngoscopy using Recist 1.1 Criteria
Secondary	Overall response rate of treatment	3 months post-radiotherapy	Overall response rate of treatment evaluated by head and neck MR/CT, laryngoscopy using Recist 1.1 Criteria
Secondary	Pathological complete response rate of the patients receiving surgical resection	Within 3 weeks after surgery	Pathological complete response rate of the patients receiving surgical resection, evaluated by experienced pathologists
Secondary	Major pathologic response rate of the patients receiving surgical resection	Within 3 weeks after surgery	Major pathologic response rate, defined as no more than 10% of residual viable tumor, evaluated by experienced pathologists.
Secondary	Overall survival rate at 1 year	One year post-radiotherapy	Overall survival rate at 1 year
Secondary	Overall survival rate at 2 year	Two year post-radiotherapy	Overall survival rate at 2 year
Secondary	Progression-free survival rate at 1 year	One year post-radiotherapy	Progression-free survival rate at 1 year
Secondary	Progression-free survival rate at 2 year	Two year post-radiotherapy	Progression-free survival rate at 2 year
Secondary	Laryngeal Preservation rate at 1 year	One year post-radiotherapy	Laryngeal Preservation rate at 1 year

1 to 10 of 16Source ClinicalTrials.gov

See all 16 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
2034244	BACKGROUND	PubMed
23182993	BACKGROUND	PubMed
23341517	BACKGROUND	PubMed
26681800	BACKGROUND	PubMed
30115475	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04995120

GET https://conductscience.org/api/trials/v1/NCT04995120/registered

API reference For AI assistants